Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib.

Onkologie - 1 Jan 2013

Bontognali Sven, Pless Miklos, Brutsche Martin H, Fischer Claude, Rochlitz Christoph, Buess Martin

Abstract excerpt

BACKGROUND: The efficacy of chemotherapy in metastatic and recurrent squamous cell carcinomas of the head and neck (HNSCC) remains unsatisfactory. Gefitinib offers a new therapeutic option with comparable results and better tolerability than chemotherapy. We conducted this study to see if mutations in the epidermal growth factor receptor (EGFR) might predict the therapeutic benefit in HNSCC patients. PATIENTS AND...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Head and Neck Neoplasms

Share to Pilot Projects

Share to Quinazolines

Share to Treatment Outcome

Source

Identifiers

PMID: 23548963
DOI: 10.1159/000349941

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib.PMID 23548963Read ↗

Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.Semantic proximity Read ↗

Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.Semantic proximity Read ↗

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative RecurrenceSemantic proximity Read ↗

Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.Semantic proximity Read ↗

A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC).Semantic proximity Read ↗

Functional mutation analysis of EGFR family genes and corresponding lymph node metastases in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.Semantic proximity Read ↗

Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response.Semantic proximity Read ↗

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.Semantic proximity Read ↗

Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck.Semantic proximity Read ↗

Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.